<?xml version="1.0" ?>
<document id="99e7ae6647b3aef265d79aa84720e5e5b584118d">
  <chunk id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c0" text="Human Anti-CCR4 Minibody Gene Transfer for the Treatment of Cutaneous T-Cell Lymphoma">
    <entity charOffset="60-85" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c0.e0" ontology_id="HP_0012192" text="Cutaneous T-Cell Lymphoma" type="phenotype"/>
    <entity charOffset="70-85" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c0.e1" ontology_id="HP_0012190" text="T-Cell Lymphoma" type="phenotype"/>
    <entity charOffset="77-85" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c0.e2" ontology_id="HP_0002665" text="Lymphoma" type="phenotype"/>
  </chunk>
  <chunk id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c1" text="Background: Although several therapeutic options have become available for patients with Cutaneous T-cell Lymphoma (CTCL), no therapy has been curative. Recent studies have demonstrated that CTCL cells overexpress the CC chemokine receptor 4 (CCR4).">
    <entity charOffset="89-114" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c1.e0" ontology_id="HP_0012192" text="Cutaneous T-cell Lymphoma" type="phenotype"/>
    <entity charOffset="99-114" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c1.e1" ontology_id="HP_0012190" text="T-cell Lymphoma" type="phenotype"/>
    <entity charOffset="106-114" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c1.e2" ontology_id="HP_0002665" text="Lymphoma" type="phenotype"/>
  </chunk>
  <chunk id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2" text="Methodology/Principal Findings: In this study, a xenograft model of CTCL was established and a recombinant adenoassociated viral serotype 8 (AAV8) vector expressing a humanized single-chain variable fragment (scFv)-Fc fusion (scFvFc or ''minibody'') of anti-CCR4 monoclonal antibody (mAb) h1567 was evaluated for curative treatment. Human CCR4 + tumorbearing mice treated once with intravenous infusion of AAV8 virions encoding the h1567 (AAV8-h1567) minibody showed anti-tumor activity in vivo and increased survival. The AAV8-h1567 minibody notably increased the number of tumorinfiltrating Ly-6G + FccRIIIa(CD16A) + murine neutrophils in the tumor xenografts over that of AAV8-control minibody treated mice. Furthermore, in CCR4 + tumor-bearing mice co-treated with AAV8-h1567 minibody and infused with human peripheral blood mononuclear cells (PBMCs), marked tumor infiltration of human CD16A + CD56 + NK cells was observed. The h1567 minibody also induced in vitro ADCC activity through both mouse neutrophils and human NK cells.">
    <entity charOffset="274-282" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e0" ontology_id="GO_0003823" text="antibody" type="gene_function"/>
    <entity charOffset="274-282" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e1" ontology_id="GO_0042571" text="antibody" type="gene_function"/>
    <entity charOffset="645-650" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e2" ontology_id="HP_0002664" text="tumor" type="phenotype"/>
    <entity charOffset="812-822" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e3" ontology_id="HP_0030646" text="peripheral" type="phenotype"/>
    <entity charOffset="863-868" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e4" ontology_id="HP_0002664" text="tumor" type="phenotype"/>
    <entity charOffset="970-974" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e5" ontology_id="GO_0001788" text="ADCC" type="gene_function"/>
    <pair e1="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e0" e2="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e2" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.p0" relation="true"/>
    <pair e1="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e0" e2="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e3" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.p1" relation="true"/>
    <pair e1="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e0" e2="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e4" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.p2" relation="true"/>
    <pair e1="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e1" e2="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e2" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.p3" relation="true"/>
    <pair e1="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e1" e2="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e3" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.p4" relation="true"/>
    <pair e1="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e1" e2="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e4" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.p5" relation="true"/>
    <pair e1="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e2" e2="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e5" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.p6" relation="true"/>
    <pair e1="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e3" e2="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e5" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.p7" relation="true"/>
    <pair e1="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e4" e2="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.e5" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c2.p8" relation="true"/>
  </chunk>
  <chunk id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c3" text="Conclusions/Significance: Overall, our data demonstrate that the in vivo anti-tumor activity of h1567 minibody is mediated, at least in part, through CD16A + immune effector cell ADCC mechanisms. These data further demonstrate the utility of the AAV-minibody gene transfer system in the rapid evaluation of candidate anti-tumor mAbs and the potency of h1567 as a potential novel therapy for CTCL.">
    <entity charOffset="179-183" id="99e7ae6647b3aef265d79aa84720e5e5b584118d.c3.e0" ontology_id="GO_0001788" text="ADCC" type="gene_function"/>
  </chunk>
</document>
